Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme

INTRODUCTION: Tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist, is approved for glycaemic control for people with type 2 diabetes (T2D). The SURPASS-1 to -5 clinical trials assessed the efficacy of once weekly tirzepatide (5, 10 and 15 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Boye, Kristina S., Thieu, Vivian Thuyanh, Sapin, Hélène, Lee, Clare J., Landó, Laura Fernández, Brown, Katelyn, Bray, Ross, Wiese, Russell J., Patel, Hiren, Rodríguez, Ángel, Yu, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570242/
https://www.ncbi.nlm.nih.gov/pubmed/37526908
http://dx.doi.org/10.1007/s13300-023-01451-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570242/
https://www.ncbi.nlm.nih.gov/pubmed/37526908
http://dx.doi.org/10.1007/s13300-023-01451-z

Ejemplares similares